Zhanxiong Luo

机构：Liuzhou General Hospital · ORCID：0000-0002-3741-4691

发表论文 30 篇 · 总被引 719 次 · h-index 9

代表论文

• Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial (2021 · The Lancet Oncology · 被引 475)
• First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer (2025 · JAMA · 被引 78)
• LINC00511/hsa-miR-573 axis-mediated high expression of Gasdermin C associates with dismal prognosis and tumor immune infiltration of breast cancer (2022 · Scientific Reports · 被引 28)
• Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial (2025 · Signal Transduction and Targeted Therapy · 被引 21)
• The Ratio of CD86+/CD163+ Macrophages Predicts Postoperative Recurrence in Stage II-III Colorectal Cancer (2021 · Frontiers in Immunology · 被引 17)
• Identification of a necroptosis-related prognostic gene signature associated with tumor immune microenvironment in cervical carcinoma and experimental verification (2022 · World Journal of Surgical Oncology · 被引 14)